<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32360804</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1542-7714</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</Title>
          <ISOAbbreviation>Clin Gastroenterol Hepatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis.</ArticleTitle>
        <Pagination>
          <StartPage>146</StartPage>
          <EndPage>154.e4</EndPage>
          <MedlinePgn>146-154.e4</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cgh.2020.04.068</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1542-3565(20)30613-3</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND &amp; AIMS">Obese patients with nonalcoholic steatohepatitis (NASH) are at risk for cirrhosis if significant weight loss is not achieved. The single fluid-filled intragastric balloon (IGB) induces meaningful weight loss and might be used in NASH treatment. We performed an open-label prospective study to evaluate the effects of IGB placement on metabolic and histologic features of NASH.</AbstractText>
          <AbstractText Label="METHODS">Twenty-one patients with early hepatic fibrosis (81% female; mean age, 54 years; average body mass index, 44 kg/m<sup>2</sup>) underwent magnetic resonance elastography (MRE) and endoscopic ultrasound with core liver biopsy collection at time IGB placement and removal at a single center from October 2016 through March 2018. The primary outcome measure was the changes in liver histology parameters after IGB, including change in nonalcoholic fatty liver disease activity score (NAS) and fibrosis score. We also evaluated changes in weight, body mass index, waist to hip ratio, aminotransaminases, fasting levels of lipids, fasting glucose, glycosylated hemoglobin, and MRE-detected liver stiffness.</AbstractText>
          <AbstractText Label="RESULTS">Six months after IGB, patients' mean total body weight loss was 11.7% ± 7.7%, with significant reductions in HbA1c (1.3% ± 0.5%) (P = .02). Waist circumference decreased by 14.4 ± 2.2 cm (P = .001). NAS improved in 18 of 20 patients (90%), with a median decrease of 3 points (range, 1-4 points); 16 of 20 patients (80%) had improvements of 2 points or more. Fibrosis improved by 1.17 stages in 15% of patients, and MRE-detected fibrosis improved by 1.5 stages in 10 of 20 patients (50%). Half of patients reached endpoints approved by the Food and Drug Administration of for NASH resolution and fibrosis improvement. Percent total body weight loss did not correlate with reductions in NAS or fibrosis. Other than post-procedural pain (in 5% of patients), no serious adverse events were reported.</AbstractText>
          <AbstractText Label="CONCLUSION">In a prospective study, IGB facilitated significant metabolic and histologic improvements in NASH. IGB appears to be safe and effective for NASH management when combined with a prescribed diet and exercise program. ClinicalTrials.gov no: NCT02880189.</AbstractText>
          <CopyrightInformation>Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bazerbachi</LastName>
            <ForeName>Fateh</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vargas</LastName>
            <ForeName>Eric J</ForeName>
            <Initials>EJ</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rizk</LastName>
            <ForeName>Monika</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maselli</LastName>
            <ForeName>Daniel B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mounajjed</LastName>
            <ForeName>Taofic</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Venkatesh</LastName>
            <ForeName>Sudhakar K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Watt</LastName>
            <ForeName>Kymberly D</ForeName>
            <Initials>KD</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Port</LastName>
            <ForeName>John D</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Basu</LastName>
            <ForeName>Rita</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Acosta</LastName>
            <ForeName>Andres</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hanouneh</LastName>
            <ForeName>Ibrahim</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gara</LastName>
            <ForeName>Naveen</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Gastroenterology and Liver Institute, Escondido, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Meera</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mundi</LastName>
            <ForeName>Manpreet</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Clark</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grothe</LastName>
            <ForeName>Karen</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Storm</LastName>
            <ForeName>Andrew C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Levy</LastName>
            <ForeName>Michael J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abu Dayyeh</LastName>
            <ForeName>Barham K</ForeName>
            <Initials>BK</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: abudayyeh.barham@mayo.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02880189</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 DK029953</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 EB001981</GrantID>
            <Acronym>EB</Acronym>
            <Agency>NIBIB NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 TR000135</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>04</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Gastroenterol Hepatol</MedlineTA>
        <NlmUniqueID>101160775</NlmUniqueID>
        <ISSNLinking>1542-3565</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015905" MajorTopicYN="Y">Gastric Balloon</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065626" MajorTopicYN="Y">Non-alcoholic Fatty Liver Disease</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Bariatric Endoscopy</Keyword>
        <Keyword MajorTopicYN="Y">Diabetes</Keyword>
        <Keyword MajorTopicYN="Y">NAFLD</Keyword>
        <Keyword MajorTopicYN="Y">Nonalcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="Y">Obesity</Keyword>
      </KeywordList>
      <CoiStatement>Conflicts of interest. These authors disclose the following: Barham K. Abu Dayyeh has served as a consultant for Metamodix, BFKW, DyaMx, Boston Scientific, and USGI medical; received research support from Apollo Endosurgery, USGI, Spatz Medical, Boston Scientific, GI Dynamics, Cairn Diagnostics, Aspire Bariatrics, and Medtronic; and served as a speaker for Johnson and Johnson, Endogastric Solutions, and Olympus. Rita Basu has received research support from AstraZeneca and served as a consultant for Genfit. Andres Acosta is founder and stockholder in Gila Therapeutics, Phenomix Sciences, and Lipiquester; has served as a consultant for Rhythm Pharmaceuticals, General Mills, Gila Therapeutics, and Phenomix Sciences; has received funding from the National Institutes of Health, Satiogen Pharmaceuticals, Vivus Pharmaceuticals, Novo Nordisk, Rhythm Pharmaceuticals, and One Ome; and has participated as co-investigator in research funded by Apollo Endosurgery. Andrew C. Storm has served as a consultant for Apollo Endosurgery; and received research support from Apollo Endosurgery and Boston Scientific. The remaining authors disclose no conflicts.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32360804</ArticleId>
        <ArticleId IdType="mid">NIHMS1688958</ArticleId>
        <ArticleId IdType="pmc">PMC8106130</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cgh.2020.04.068</ArticleId>
        <ArticleId IdType="pii">S1542-3565(20)30613-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hales CM, Carroll MD, Fryar CD, et al.
Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief No. 288
2017. Available at: https://www.cdc.gov/nchs/data/databriefs/db288.pdf.
Accessed
January 23, 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29155689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams LA, Lymp JF, St Sauver J, et al.
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology
2005;129:113–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16012941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Promrat K, Kleiner DE, Niemeier HM, et al.
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology
2010;51:121–129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2799538</ArticleId>
            <ArticleId IdType="pubmed">19827166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>English WJ, DeMaria E, Hutter M, et al.
American Society for Metabolic and Bariatric Surgery 2018 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis
2020;16:457–463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32029370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazerbachi F, Vargas Valls EJ, Abu Dayyeh BK. Recent clinical results of endoscopic bariatric therapies as an obesity intervention. Clin Endosc
2017;50:42–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5299988</ArticleId>
            <ArticleId IdType="pubmed">28147472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazerbachi F, Vargas EJ, Abu Dayyeh BK. Endoscopic bariatric therapy: a guide to the intragastric balloon. Am J Gastroenterol
2019;114:1421–1431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31082868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazerbachi F, Haffar S, Sawas T, et al.
Fluid-filled versus gas-filled intragastric balloons as obesity interventions: a network meta-analysis of randomized trials. Obes Surg
2018;28:2617–2625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29663250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Food and Drug Administration. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment: guidance for industry. 2018. Available at: https://www.fda.gov/media/119044/download.
Accessed
January 23, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Kumar N, Bazerbachi F, Rustagi T, et al.
The influence of the orbera intragastric balloon filling volumes on weight loss, tolerability, and adverse events: a systematic review and meta-analysis. Obes Surg
2017;27:2272–2278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28285471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu Dayyeh BK, Bazerbachi F, Graupera I, et al.
Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease. J Hepatol
2019;71:1246–1248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31570275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mion F, Napoleon B, Roman S, et al.
Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg
2005;15:510–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15946431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariani S, Fiore D, Persichetti A, et al.
Circulating SIRT1 increases after intragastric balloon fat loss in obese patients. Obes Surg
2016;26:1215–1220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26337692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannah WN Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis
2016;20:339–350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27063273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.
Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology
2015;149:367–378.e5; quiz e14–e15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25865049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nickel F, Tapking C, Benner L, et al.
Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up. Obes Surg
2018;28:1342–1350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29119336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armstrong MJ, Gaunt P, Aithal GP, et al.
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet
2016;387:679–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26608256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanyal AJ, Chalasani N, Kowdley KV, et al.
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med
2010;362:1675–1685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2928471</ArticleId>
            <ArticleId IdType="pubmed">20427778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cusi K, Orsak B, Bril F, et al.
Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med
2016;165:305–315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27322798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Younossi ZM, Ratziu V, Loomba R, et al.
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet
2019;394:2184–2196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31813633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhandari M, Fobi MAL, Buchwald JN, et al.
Standardization of bariatric metabolic procedures: World Consensus Meeting statement. Obes Surg
2019;29:309–345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31297742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keleidari B, Mahmoudieh M, Gorgi K, et al.
Hepatic failure after bariatric surgery: a systematic review. Hepat Mon
2019;19:e86078.</Citation>
        </Reference>
        <Reference>
          <Citation>Vargas EJ, Pesta CM, Bali A, et al.
Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol
2018;16:1073–1080.e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6008169</ArticleId>
            <ArticleId IdType="pubmed">29425781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosli MM, Elyas M. Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?
Saudi J Gastroenterol
2017;23:117–122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5385714</ArticleId>
            <ArticleId IdType="pubmed">28361843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazerbachi F, Vargas EJ, Mounajjed T, et al.
795 Impact of single fluid-filled intragastric balloon on metabolic parameters and nonalcoholic steatohepatitis: a prospective paired endoscopic ultrasound guided core liver biopsy at the time of balloon placement and removal. Gastrointest Endosc
2018;87:AB118–AB119.</Citation>
        </Reference>
        <Reference>
          <Citation>Bazerbachi F, Vargas E, Maselli DB, et al.
Su1273 endosonographic estimation of the celiac artery mesenteric fat thickness (cameus) is a novel reliable anthropomorphic correlate of obesity and obesity-associated steatohepatitis: a proof-of-concept prospective controlled study and technique description. Gastrointestinal Endoscopy
2020;91:AB305.</Citation>
        </Reference>
        <Reference>
          <Citation>Bazerbachi F, Vargas EJ, Matar R, et al.
EUS-guided core liver biopsy sampling using a 22-gauge fork-tip needle: a prospective blinded trial for histologic and lipidomic evaluation in nonalcoholic fatty liver disease. Gastrointest Endosc
2019;90:926–932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31437454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stefan N, Häring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol
2019;7:313–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30174213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centis E, Moscatiello S, Bugianesi E, et al.
Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. J Hepatol
2013;58:771–777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23201248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naveau S, Lamouri K, Pourcher G, et al.
The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obes Surg
2014;24:1693–1701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24841950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kenngott HG, Clemens G, Gondan M, et al.
DiaSurg 2 trial–surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial–DRKS00004550. Trials
2013;14:183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3694456</ArticleId>
            <ArticleId IdType="pubmed">23782896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazerbachi F, Haffar S, Wang Z, et al.
Range of normal liver stiffness and factors associated with increased stiffness measurements in apparently healthy individuals. Clin Gastroenterol Hepatol
2019;17:54–64.e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30196155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han MAT, Altayar O, Hamdeh S, et al.
Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol
2019;17:616–629.e26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29913275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szanto KB, Li J, Cordero P, et al.
Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes
2019;12:357–367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6430068</ArticleId>
            <ArticleId IdType="pubmed">30936733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazerbachi F, Vargas EJ, Abu Dayyeh BK. Endoscopic bariatric therapy: a guide to the intragastric balloon. Am J Gastroenterol
2019;114:1421–1431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31082868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bazerbachi F, Vargas EJ, Matar R, et al.
EUS-guided core liver biopsy sampling using a 22-gauge fork-tip needle: a prospective blinded trial for histologic and lipidomic evaluation in nonalcoholic fatty liver disease. Gastrointest Endosc
2019;90:926–932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31437454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rockey DC, Caldwell SH, Goodman ZD, et al.
Liver biopsy. Hepatology
2009;49:1017–1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19243014</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
